alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › post-marketing

post-marketing

4 studies tagged post-marketing, dated 2026-03-06 to 2026-08-18. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study 2026-08-18
  2. Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology 2026-06-22
  3. Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer's disease 2026-03-17

Studies

4 studies carry this tag.

Date range

2026

Top journals

  • Frontiers in psychiatry 1
  • Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 1
  • The journal of prevention of Alzheimer's disease 1
  • Therapeutic advances in drug safety 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Therapeutic advances in drug safety 2026-08-18 Treatments

    FAERS included 2961 lecanemab and 1542 donanemab primary suspect reports; WHO-VigiAccess included 2525 lecanemab- and 1450 donanemab-related reports.

  2. Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Frontiers in psychiatry 2026-06-22 Treatments

    This study provides real-world evidence on the risk profile of lecanemab, highlighting the importance of continued safety monitoring.

  3. Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. The journal of prevention of Alzheimer's disease 2026-03-17 Treatments

    This interim analysis represents one of the largest real-world lecanemab cohorts reported globally to date.

  4. Regulatory, clinical, and post-marketing challenges of lecanemab for Alzheimer's disease: insights from real-world data

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026-03-06 Treatments

    Four regulatory agencies have approved lecanemab through different pathways, each requiring confirmation of amyloid pathology and careful assessment of ARIA risk, particularly in Apolipoprotein E (ApoE) ε4 homozygotes.

All topic tags with their study counts